

Carbapenem-resistant *Enterobacteriaceae* and *Candida auris*

Surveillance Report

January 2021- March, 2021

Carbapenem-resistant *Enterobacteriaceae* (CRE): January 2021—March 2021

Carbapenemase-Producing (CP) Status of Confirmed Cases

CP-CRE	34 (73.9%)
Non-CP CRE	5 (10.9%)
CP Status Pending/Not Tested	7 (15.2%)
Total Confirmed CRE Cases	46

CP testing capabilities of 14 clinical laboratories in Philadelphia (as of Spring 2020)



Detection Method	n (%)
Carba NP, Modified Hodge, or other phenotypic testing only	2 (14%)
PCR or other genotypic testing	3 (22%)
No regular CP testing	9 (64%)

CRE Counts¹, by Genus Species and Mechanism (n=47)

Genus Species	Total CRE n (%)	Total CP-CRE	KPC	NDM	OXA-48	IMP	VIM
<i>Klebsiella pneumoniae</i>	20 (43.4)	17	15	1	1	.	.
<i>Escherichia coli</i>	8 (17.4)	5	3	2	1	.	.
<i>Enterobacter cloacae</i>	10 (21.7)	6	4	1	.	.	.
<i>Citrobacter freundii</i>	3 (6.5)	3	2	2	.	.	.
<i>Enterobacter aerogenes</i>	3 (6.5)	1	1
<i>Klebsiella oxytoca</i>	1 (2.2)	1	1
<i>Other Citrobacter spp.</i>	1 (2.2)	1	1
Total	46	34	29	6	2	0	0


¹not all isolates sent for mechanism testing, some isolates have more than one mechanism

CRE Cases, by Carbapenemase-Producing (CP) Status: April 2020—March 2021



Candida auris Report

Candida auris Cases in Philadelphia by Month



Candida auris is an emerging threat in the Philadelphia region. The first *C. auris* case was reported in March 2020 in an individual who likely acquired the organism out of state, however, the cases in August, September, October, and March are part of a local healthcare facility cluster. For more information, see the [joint Health Alert by PDPH and PA DOH](#) or the [C. auris webpage on the PDPH Health Information Portal](#).

Suspected or confirmed cases of *C. auris* should be reported to PDPH by calling 215-685-6748 within 24 hours. Complete the [Candida auris Report Form](#) and fax to 215-238-6947 **after reporting the case by phone.**